ClinicalTrials.gg

Program

dexketoprofen

Also written as “Dexketoprofen Trometamol + Tramadol Hydrochloride”, “Dexketoprofen/Tramadol-single dose” and “Dexketoprofen/Tramadol-multiple doses”.

Its studies are mostly in Acute Pain · Dysmenorrhea · Low Back Pain · Venous Thrombosis · Pain, led by 2 companies.

Furthest: phase 4, since May 13, 20168 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Menarini Group60 open or runningphase 4since May 13, 2016Feb 28, 2011none ahead
Laboratorios Silanes S.A. de C.V.20 open or runningphase 3since Jul 29, 2021Jul 29, 2021none ahead

Also a collaborator on its studies: simbec-research and pra-health-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 28, 2011First study: phase 2 study in PainNew to Menarini GroupMenarini Group · NCT01307020 · 745 enrolled · Germany, Hungary, Italy and more
  2. Jun 14, 2013Phase 3 study in Venous ThrombosisMenarini Group · NCT01880216 · 312 enrolled · Georgia, Russian Federation
  3. Jul 15, 20132 phase 3 studies in Acute PainMenarini Group · NCT01902134, NCT01904149
  4. Aug 4, 2014Phase 1 study in Acute PainMenarini Group · NCT02209454 · 26 enrolled · United Kingdom
  5. May 13, 2016Phase 4 study in Acute PainMenarini Group · NCT02777970 · 654 enrolled · Hungary, Italy, Poland and more
  6. Jul 29, 2021Laboratorios Silanes S.A. de C.V.'s first study: phase 3 study in Acute Low Back PainNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT05001555 · 174 enrolled · Mexico
  7. Oct 14, 2026Phase 3 study in Primary DysmenorrheaLaboratorios Silanes S.A. de C.V. · NCT07901894 · 130 enrolled · Mexico

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07901894Primary Dysmenorrhea · Mexico3CompletedLaboratorios Silanes S.A. de C.V.May 7, 2026130
NCT05001555Acute Low Back Pain · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Apr 24, 2023174
NCT02777970Acute Pain · Hungary, Italy, Poland and more4CompletedMenarini GroupFeb 14, 2017654
NCT02209454Acute Pain · United Kingdom1CompletedMenarini GroupMay 201426
NCT01904149Acute Pain · Hungary, Latvia, Lithuania and more3CompletedMenarini GroupMay 2014606
NCT01902134Acute Pain · Czech Republic, Germany, Hungary and more3CompletedMenarini GroupFeb 2014641
NCT01880216Venous Thrombosis · Georgia, Russian Federation3CompletedMenarini GroupJan 2015312
NCT01307020Pain · Germany, Hungary, Italy and more2CompletedMenarini GroupOct 2011745

How it is read

Names in the registry

  • “Dexketoprofen Trometamol + Tramadol Hydrochloride”, 4 entries
  • “Dexketoprofen/Tramadol-single dose”, 2 entries
  • “Dexketoprofen/Tramadol-multiple doses”, 2 entries
  • “Dexketoprofen / Butylscopolamine in fixed dose combination tablet. (Laboratorios Silanes S.A. de C.V.)”, 1 entry
  • “Dexketoprofen/Vitamin B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.